Search Results - "LAHUERTA, Juan Jose"

Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials by Lahuerta, Juan-Jose, Paiva, Bruno, Vidriales, Maria-Belen, Cordón, Lourdes, Cedena, Maria-Teresa, Puig, Noemi, Martinez-Lopez, Joaquin, Rosiñol, Laura, Gutierrez, Norma C, Martín-Ramos, María-Luisa, Oriol, Albert, Teruel, Ana-Isabel, Echeveste, María-Asunción, de Paz, Raquel, de Arriba, Felipe, Hernandez, Miguel T, Palomera, Luis, Martinez, Rafael, Martin, Alejandro, Alegre, Adrian, De la Rubia, Javier, Orfao, Alberto, Mateos, María-Victoria, Blade, Joan, San-Miguel, Jesus F

“…Purpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed…”
Get full text

The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements by Cedena, Maria-Teresa, Martin-Clavero, Estela, Wong, Sandy, Shah, Nina, Bahri, Natasha, Alonso, Rafael, Barcenas, Carmen, Valeri, Antonio, Salazar Tabares, Johny, Sanchez-Pina, Jose, Cuellar, Clara, Martin, Thomas, Wolf, Jeffrey, Lahuerta, Juan-Jose, Martinez-Lopez, Joaquin

“…Background Stringent complete response (sCR) is used as a deeper response category than complete response (CR) in multiple myeloma (MM) but may be of limited…”
Get full text

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma by Medina, Alejandro, Puig, Noemi, Flores-Montero, Juan, Jimenez, Cristina, Sarasquete, M.-Eugenia, Garcia-Alvarez, María, Prieto-Conde, Isabel, Chillon, Carmen, Alcoceba, Miguel, Gutierrez, Norma C., Oriol, Albert, Rosinol, Laura, Bladè, Joan, Gironella, Mercedes, Hernandez, Miguel T., Gonzalez-Calle, Veronica, Cedena, Maria-Teresa, Paiva, Bruno, San-Miguel, Jesus F., Lahuerta, Juan-Jose, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Orfao, Alberto, Gonzalez, Marcos, Garcia-Sanz, Ramon

“…Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have…”
Get full text

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma by PAIVA, Bruno, MARTINEZ-LOPEZ, Joaquin, LARANA, José-Garcia, BENGOECHEA, Enrique, MARTIN, Alejandro, DIAZ MEDIAVILLA, Joaquin, PALOMERA, Luis, DE ARRIBA, Felipe, BLADE, Joan, ORFAO, Alberto, LAHUERTA, Juan-Jose, SAN MIGUEL, Jesus F, VIDRIALES, Maria-Belen, MATEOS, Maria-Victoria, MONTALBAN, Maria-Angeles, FERNANDEZ-REDONDO, Elena, ALONSO, Lourdes, ORIOL, Albert, TERUEL, Ana-Isabel, DE PAZ, Raquel

“…To investigate the impact of immunophenotypic response (IR) versus complete response (CR) and CR plus normal serum free light chain (sFLC) ratio (stringent CR)…”
Get full text

Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis by Puig, Noemi, Paiva, Bruno, Lasa, Marta, Burgos, Leire, Perez, Jose J., Merino, Juana, Moreno, Cristina, Vidriales, Maria-Belen, Toboso, Dolores Gómez, Cedena, Maria-Teresa, Ocio, Enrique M., Lecumberri, Ramon, García de Coca, Alfonso, Labrador, Jorge, Gonzalez, Maria-Esther, Palomera, Luis, Gironella, Mercedes, Cabañas, Valentin, Casanova, Maria, Oriol, Albert, Krsnik, Isabel, Pérez-Montaña, Albert, de la Rubia, Javier, de la Puerta, Jose-Enrique, de Arriba, Felipe, Prosper, Felipe, Martinez-Lopez, Joaquin, Lecrevisse, Quentin, Verde, Javier, Mateos, Maria-Victoria, Lahuerta, Juan-Jose, Orfao, Alberto, San Miguel, Jesús F.

“…Early diagnosis and risk stratification are key to improve outcomes in light-chain (AL) amyloidosis. Here we used multidimensional-flow-cytometry (MFC) to…”
Get full text

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group by Mosquera Orgueira, Adrian, González Pérez, Marta Sonia, Diaz Arias, Jose, Rosiñol, Laura, Oriol, Albert, Teruel, Ana Isabel, Martinez Lopez, Joaquin, Palomera, Luis, Granell, Miguel, Blanchard, Maria Jesus, de la Rubia, Javier, López de la Guia, Ana, Rios, Rafael, Sureda, Anna, Hernandez, Miguel Teodoro, Bengoechea, Enrique, Calasanz, María José, Gutierrez, Norma, Martin, Maria Luis, Blade, Joan, Lahuerta, Juan-Jose, San Miguel, Jesús, Mateos, Maria Victoria

“…The International Staging System (ISS) and the Revised International Staging System (R-ISS) are commonly used prognostic scores in multiple myeloma (MM). These…”
Get full text

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy by Mateos, María-Victoria, Bringhen, Sara, Richardson, Paul G, Lahuerta, Juan Jose, Larocca, Alessandra, Oriol, Albert, Boccadoro, Mario, García-Sanz, Ramón, Di Raimondo, Francesco, Esseltine, Dixie-Lee, van de Velde, Helgi, Desai, Avinash, Londhe, Anil, San Miguel, Jesús F, Palumbo, Antonio

“…Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various…”
Get full text

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project by D'Agostino, Mattia, Cairns, David A, Lahuerta, Juan José, Wester, Ruth, Bertsch, Uta, Waage, Anders, Zamagni, Elena, Mateos, María-Victoria, Dall'Olio, Daniele, van de Donk, Niels W C J, Jackson, Graham, Rocchi, Serena, Salwender, Hans, Bladé Creixenti, Joan, van der Holt, Bronno, Castellani, Gastone, Bonello, Francesca, Capra, Andrea, Mai, Elias K, Dürig, Jan, Gay, Francesca, Zweegman, Sonja, Cavo, Michele, Kaiser, Martin F, Goldschmidt, Hartmut, Hernández Rivas, Jesús María, Larocca, Alessandra, Cook, Gordon, San-Miguel, Jesús F, Boccadoro, Mario, Sonneveld, Pieter

“…Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the…”
Get full text

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma by Mateos, María-Victoria, Hernández, Miguel-Teodoro, Giraldo, Pilar, de la Rubia, Javier, de Arriba, Felipe, Corral, Lucía López, Rosiñol, Laura, Paiva, Bruno, Palomera, Luis, Bargay, Joan, Oriol, Albert, Prosper, Felipe, López, Javier, Olavarría, Eduardo, Quintana, Nuria, García, José-Luis, Bladé, Joan, Lahuerta, Juan-José, San Miguel, Jesús-F

“…Certain clinical features predict progression from smoldering to overt multiple myeloma. Patients with high-risk features who were treated with lenalidomide…”
Get full text

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma by Garcés, Juan-Jose, Cedena, Maria-Teresa, Puig, Noemi, Burgos, Leire, Perez, Jose J, Cordon, Lourdes, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Calasanz, Maria-Jose, Ortiol, Albert, Blanchard, María-Jesús, Rios, Rafael, Martin, Jesus, Martínez-Martinez, Rafael, Bargay, Joan, Sureda, Anna, de la Rubia, Javier, Hernandez, Miguel-Teodoro, Rodriguez-Otero, Paula, de la Cruz, Javier, Orfao, Alberto, Mateos, Maria-Victoria, Martinez-Lopez, Joaquin, Lahuerta, Juan-Jose, Rosiñol, Laura, Blade, Joan, San-Miguel, Jesus F, Paiva, Bruno

“…Patients with multiple myeloma (MM) may show patchy bone marrow (BM) infiltration and extramedullary disease. Notwithstanding, quantification of plasma cells…”
Get full text

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma by Rajkumar, S Vincent, Prof, Dimopoulos, Meletios A, Prof, Palumbo, Antonio, Prof, Blade, Joan, Md, Merlini, Giampaolo, Prof MD, Mateos, María-Victoria, MD, Kumar, Shaji, Prof, Hillengass, Jens, MD, Kastritis, Efstathios, MD, Richardson, Paul, Prof, Landgren, Ola, MD, Paiva, Bruno, MD, Dispenzieri, Angela, Prof, Weiss, Brendan, MD, LeLeu, Xavier, MD, Zweegman, Sonja, Prof, Lonial, Sagar, Prof, Rosinol, Laura, MD, Zamagni, Elena, MD, Jagannath, Sundar, Prof, Sezer, Orhan, Prof, Kristinsson, Sigurdur Y, MD, Caers, Jo, MD, Usmani, Saad Z, MD, Lahuerta, Juan José, MD, Johnsen, Hans Erik, Prof, Beksac, Meral, Prof, Cavo, Michele, Prof, Goldschmidt, Hartmut, Prof, Terpos, Evangelos, MD, Kyle, Robert A, Prof, Anderson, Kenneth C, Prof, Durie, Brian G M, Prof, Miguel, Jesus F San, Prof

“…Summary This International Myeloma Working Group consensus updates the disease definition of multiple myeloma to include validated biomarkers in addition to…”
Get full text

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma by Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, María Jesús, Hernández, Miguel Teodoro, Martínez-Martínez, Rafael, Moraleda, Jose M., Jarque, Isidro, Bargay, Juan, Gironella, Mercedes, de Arriba, Felipe, Palomera, Luis, González-Montes, Yolanda, Martí, Josep M., Krsnik, Isabel, Arguiñano, Jose M., González, Maria Esther, González, Ana Pilar, Casado, Luis Felipe, López-Anglada, Lucia, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Bladé, Joan

“…Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012…”
Get full text

Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial by Mateos, María-Victoria, Dr, Hernández, Miguel-Teodoro, MD, Giraldo, Pilar, MD, de la Rubia, Javier, MD, de Arriba, Felipe, PhD, Corral, Lucía López, PhD, Rosiñol, Laura, PhD, Paiva, Bruno, PhD, Palomera, Luis, PhD, Bargay, Joan, PhD, Oriol, Albert, MD, Prosper, Felipe, PhD, López, Javier, PhD, Arguiñano, José-María, MD, Quintana, Nuria, MD, García, José-Luis, MD, Bladé, Joan, PhD, Lahuerta, Juan-José, PhD, Miguel, Jesús-F San, Prof

“…Summary Background The standard of care for smouldering multiple myeloma is observation. We did the QuiRedex study to compare early treatment with lenalidomide…”
Get full text

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma by Goicoechea, Ibai, Puig, Noemi, Cedena, Maria-Teresa, Burgos, Leire, Cordón, Lourdes, Vidriales, María-Belén, Flores-Montero, Juan, Gutierrez, Norma C., Calasanz, Maria-Jose, Ramos, Maria-Luisa Martin, Lara-Astiaso, David, Vilas-Zornoza, Amaia, Alignani, Diego, Rodriguez, Idoia, Sarvide, Sarai, Alameda, Daniel, Garcés, Juan José, Rodriguez, Sara, Fresquet, Vicente, Celay, Jon, Garcia-Sanz, Ramón, Martinez-Lopez, Joaquin, Oriol, Albert, Rios, Rafael, Martin-Sanchez, Jesus, Martinez-Martinez, Rafael, Sarra, Josep, Hernandez, Miguel-Teodoro, de la Rubia, Javier, Krsnik, Isabel, Moraleda, Jose-Maria, Palomera, Luis, Bargay, Joan, Martinez-Climent, Jose-Angel, Orfao, Alberto, Rosiñol, Laura, Mateos, Maria-Victoria, Lahuerta, Juan-José, Blade, Joan, San Miguel, Jesús, Paiva, Bruno

“…Patients with multiple myeloma (MM) carrying standard- or high-risk cytogenetic abnormalities (CAs) achieve similar complete response (CR) rates, but the later…”
Get full text

Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials by SONNEVELD, Pieter, GOLDSCHMIDT, Hartmut, DESAI, Avinash, CAKANA, Andrew, LIU, Kevin, VAN DE VELDE, Helgi, ESSELTINE, Dixie-Lee, MOREAU, Philippe, ROSIÑOL, Laura, BLADE, Joan, JOSE LAHUERTA, Juan, CAVO, Michele, TACCHETTI, Paola, ZAMAGNI, Elena, ATTAL, Michel, LOKHORST, Henk M

“…To characterize efficacy and safety of bortezomib-based versus nonbortezomib-based induction regimens through an integrated analysis of data from phase III…”
Get full text

Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1‐acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group by Ocio, Enrique M., Motlló, Cristina, Rodríguez‐Otero, Paula, Martínez‐López, Joaquín, Cejalvo, Mª José, Martín‐Sánchez, Jesús, Bladé, Joan, García‐Malo, Mª Dolores, Dourdil, Mª Victoria, García‐Mateo, Aránzazu, Arriba, Felipe, García‐Sanz, Ramón, Rubia, Javier, Oriol, Albert, Lahuerta, Juan‐José, San‐Miguel, Jesús F., Mateos, María‐Victoria

“…Summary This phase I/II trial evaluated the combination of the kinesin spindle protein inhibitor filanesib with pomalidomide and dexamethasone in relapsed or…”
Get full text

Measurable Residual Disease by Mass Spectrometry and Next-Generation Flow to Assess Treatment Response in Myeloma by Puig, Noemi, Agullo Roca, Cristina, Sanfeliciano, Teresa Contreras, Cedena, M Teresa, Martínez-López, Joaquín, Oriol, Albert, Blanchard, María-Jesús, Ríos-Tamayo, Rafael, Iñigo Rodríguez, Belén, Sureda, Anna, Lakhwani, Sunil, de la Rubia Comos, Javier, Gonzalez-Calle, Veronica, Cabañas, Valentín, Palomera, Luis, Moraleda, José María M, Bargay, Joan, Castro, Sergio, Rosiñol, Laura, Bladé, Joan, San-Miguel, Jesús F, Lahuerta, Juan-Jose, Paiva, Bruno, Mateos, Maria-Victoria

“…Quantitative immuneprecipitation mass-spectrometry (QIP-MS) allows the identification of the M-protein in patients with multiple myeloma (MM) otherwise in…”
Get full text

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials by Bringhen, Sara, Mateos, Maria Victoria, Zweegman, Sonja, Larocca, Alessandra, Falcone, Antonietta Pia, Oriol, Albert, Rossi, Davide, Cavalli, Maide, Wijermans, Pierre, Ria, Roberto, Offidani, Massimo, Lahuerta, Juan Jose, Liberati, Anna Marina, Mina, Roberto, Callea, Vincenzo, Schaafsma, Martijn, Cerrato, Chiara, Marasca, Roberto, Franceschini, Luca, Evangelista, Andrea, Teruel, Ana-Isabel, van der Holt, Bronno, Montefusco, Vittorio, Ciccone, Giovannino, Boccadoro, Mario, San Miguel, Jesus, Sonneveld, Pieter, Palumbo, Antonio

“…Thalidomide and bortezomib are extensively used to treat elderly myeloma patients. In these patients, treatment-related side effects are frequent and full drug…”
Get full text

Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies by Burgos, Leire, Tamariz-Amador, Luis-Esteban, Puig, Noemi, Cedena, Maria-Teresa, Guerrero, Camila, Jelínek, Tomas, Johnson, Sarah, Milani, Paolo, Cordon, Lourdes, Perez, Jose J, Lasa, Marta, Termini, Rosalinda, Oriol, Albert, Hernandez, Miguel-Teodoro, Palomera, Luis, Martinez-Martinez, Rafael, de la Rubia, Javier, de Arriba, Felipe, Rios, Rafael, Gonzalez, Maria-Esther, Gironella, Mercedes, Cabañas, Valentin, Casanova, Maria, Krsnik, Isabel, Perez-Montaña, Albert, González-Calle, Verónica, Rodriguez-Otero, Paula, Maisnar, Vladimir, Hajek, Roman, Van Rhee, Fritz, Jimenez-Zepeda, Victor, Palladini, Giovanni, Merlini, Giampaolo, Orfao, Alberto, de la Cruz, Javier, Martinez-Lopez, Joaquin, Lahuerta, Juan-Jose, Rosiñol, Laura, Blade, Joan, Mateos, Maria-Victoria, San-Miguel, Jesus F, Paiva, Bruno

“…The existence of patients with multiple myeloma (MM) and light-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance…”
Get full text

Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma by Garcés, Juan-José, Bretones, Gabriel, Burgos, Leire, Valdes-Mas, Rafael, Puig, Noemi, Cedena, Maria-Teresa, Alignani, Diego, Rodriguez, Idoia, Puente, Diana Álvarez, Álvarez, Miguel-García, Goicoechea, Ibai, Rodriguez, Sara, Calasanz, Maria-Jose, Agirre, Xabier, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Rodriguez-Otero, Paula, Rios, Rafael, Martinez-Lopez, Joaquin, Millacoy, Pamela, Palomera, Luis, Del Orbe, Rafael, Pérez-Montaña, Albert, El Omri, Halima, Prosper, Felipe, Mateos, Maria-Victoria, Rosiñol, Laura, Blade, Joan, Lahuerta, Juan-Jose, Orfao, Alberto, Lopez-Otin, Carlos, San Miguel, Jesus F., Paiva, Bruno

“…Multiple myeloma (MM) patients undergo repetitive bone marrow (BM) aspirates for genetic characterization. Circulating tumor cells (CTCs) are detectable in…”
Get full text